Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of purinostat mesylate for injection versus selinexor in relapsed/refractory diffuse large B-cell lymphoma
CTR20252401Phase 3Active
- Sponsor
- Guizhou Bailing Group Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of purinostat, selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Guizhou Bailing Group Pharmaceutical Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
purinostatselinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20252401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252401.